Our Ref: 383 May 2024



## Re: Your request made under the Freedom of Information Act 2000

I am analysing the usage of new biologic and targeted medications within dermatology medicine. Could you please answer the following question:

How many patients were treated in May 2024 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibingo) 0
- Baricitinib (Olumiant) 3
- Dupilumab (Dupixent) 15
- Lebrikizumab (Ebglyss) 0
- Tralokinumab (Adtralza) 0
- Upadacitinib (Rinvoq) 0